In an interview with ONCOLOGY®, Evan B. Bryson, PharmD, BCOP, offers a comprehensive review of real-world treatment considerations of amivantamab as therapy for patients with non–small cell lung cancer.
Evan B. Bryson, PharmD, BCOP
Advertisement
Articles by Evan B. Bryson, PharmD, BCOP
Advertisement
Latest Updated Articles
Expert Commentary on the Product Profile of Amivantamab-vmjwPublished: March 12th 2022 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: Which Presentations Will Move the Multiple Myeloma Needle?
2
ASH 2025: Key Anticipated Updates in the Leukemia Landscape
3
FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy
4
FDA and EMA Clear Phase 3 POLARIS-1 Trial in Newly Diagnosed Ph+ ALL
5
